BIO 2020: Building your first patent portfolio

For a start-up looking to build a patent portfolio, where should you start—‘home-grown’ patents, or licensing others’ IP?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

BIO 2020: AI patents and secrets

16 June 2020 Discussions around artificial intelligence (AI) and IP can sometimes be futuristic and trapped at the level of high-concept: whether machines can be inventors, for example. But at BIO Digital 2020, a panel of experts was on hand to provide a much more practical, down-to-earth guide to patenting AI inventions.

Americas

BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling

9 June 2020 Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

Big Pharma

Former Genentech employee cuts plea deal with FBI in trade secrets case

16 January 2020 A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

BIO 2020: Building your first patent portfolio

More on this story

Editor's picks

Editor's picks

More features